Arecor CEO on Skye Bioscience partnership and the value of collaborations

Proactive - Interviews for investors

Arecor Therapeutics PLC (AIM:AREC) CEO Sarah Howell talked with Proactive's Stephen Gunnion about the company's growing revenue streams, key partnerships, and ongoing developments within its proprietary pipeline. Howell discussed a new formulation development collaboration with Skye Bioscience, which aims to enhance Skye’s CB1 inhibitor, nimacimab, currently in Phase II trials. The formulation will leverage Arecor’s proprietary Arestat™ platform, with the goal of achieving higher concentration formats that can reduce dosing frequency and improve patient adherence. She noted that this is the third partnership Arecor has announced in 2025, highlighting the demand from pharmaceutical partners for the company's technology. “These are with enhanced properties. They bring improvements patients that are otherwise unachievable,” Howell said. Arecor currently has three products under license, including AT220, launched globally in late 2023 and now generating royalties. Products in development with Sanofi and another specialty pharmaceutical company, including AT351, also represent long-term revenue potential through milestone and royalty agreements. Looking ahead, Howell pointed to a strong pipeline focused on diabetes and obesity, including its proprietary ultra-concentrated insulin AT278, and a novel oral peptide delivery platform with expected preclinical data in H2 2025. Visit Proactive’s YouTube channel for more interviews like this. Don’t forget to like this video, subscribe to our channel, and enable notifications so you never miss an update. #ArecorTherapeutics #BiotechNews #PharmaceuticalPartnership #DiabetesInnovation #ObesityTreatment #InsulinDevelopment #AT220 #AT278 #OralPeptideDelivery #ProactiveInvestors